Loading organizations...
§ Private Profile · Daejeon, Taejon-jikhalsi, South Korea
Clinical-stage biotechnology company developing off-the-shelf NK cell and CAR-NK therapies for hematologic malignancies and solid.
Ingenium Therapeutics is a clinical-stage biotechnology company developing off-the-shelf NK cell therapies for hematologic malignancies and novel in vivo 5th generation CAR-NK therapies for solid tumors, based in Daejeon, South Korea. The company has secured $9.94 million in total funding, with $910,000 raised approximately one year ago, and maintains a team of 10-50 employees. Its pipeline includes IGNK-002, currently in Phase 2 trials for acute myeloid leukemia, and Gengluecel, approved for Phase 2 by the Korean Ministry of Food and Drug Safety. Additionally, its IGNK001 NK cell therapy received US FDA Orphan Drug Designation on April 30, 2024. Led by CEO Ko Jin-ok, Ingenium Therapeutics originated as a spin-off from the Korea Research Institute of Biosciences and Biotechnology (KRIBB) and was founded in 2020.
Ingenium Therapeutics has raised $13.3M across 3 funding rounds.
Ingenium Therapeutics has raised $13.3M in total across 3 funding rounds.
Ingenium Therapeutics has raised $13.3M in total across 3 funding rounds.
Ingenium Therapeutics's investors include Capstone Partners, KGround, Kairos Investment, LaPlace, Maple VC.
Ingenium Therapeutics has raised $13.3M across 3 funding rounds. Most recently, it raised $4.2M Series B in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 27, 2026 | $4.2M Series B | — | — | Announced |
| Nov 21, 2023 | $4.1M Series A | — | Capstone Partners, Kground | Announced |
| Apr 13, 2022 | $5M Seed Plus | — | Capstone Partners, Kairos Investment, Kground, Laplace, Maple VC | Announced |